B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN icon
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
51
Harrow
HROW
$1.03B
$1.67M 0.05%
125,967
-1,372,617
-92% -$14.6M
2023 Q1
4 quarters
AMGN icon
52
Amgen
AMGN
$231B
– –
-58,200
Closed -$16.8M –
CMPX icon
53
Compass Therapeutics
CMPX
$149M
– –
-317,761
Closed -$496K –
DNLI icon
54
Denali Therapeutics
DNLI
$2.84B
– –
-461,769
Closed -$9.91M –
DYN icon
55
Dyne Therapeutics
DYN
$2.8B
– –
-755,811
Closed -$10.1M –
HLVX icon
56
DELISTED
HilleVax
HLVX
– –
-203,407
Closed -$3.26M –
IMCR icon
57
Immunocore
IMCR
$1.46B
– –
-611,365
Closed -$41.8M –
LNTH icon
58
Lantheus
LNTH
$6.54B
– –
-495,100
Closed -$30.7M –
MRUS icon
59
DELISTED
Merus
MRUS
– –
-370,679
Closed -$10.2M –
RAPT icon
60
DELISTED
RAPT Therapeutics
RAPT
– –
-48,663
Closed -$9.67M –
TERN icon
61
DELISTED
Terns Pharmaceuticals
TERN
– –
-2,318,050
Closed -$15M –
THRD icon
62
DELISTED
Third Harmonic Bio
THRD
– –
-1,316,018
Closed -$14.4M –
VRDN icon
63
Viridian Therapeutics
VRDN
$2.09B
– –
-323,102
Closed -$7.04M –
1 2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.